Sexual differentiation of the male and female reproductive tracts in mammalian embryos is a complex process originating from a common starting point with both genetic males and females initially having bipotential gonads and paired Müllerian (paramesonephric) and Wolffian (mesonephric) ducts. The Wolffian ducts are the progenitors of the epididymis, vas deferens, and seminal vesicles in males, whereas the Müllerian ducts become the fallopian tubes, uterus, and part of the vagina in females [1, 2] . The first step in sex determination occurs when the sex determining region Y gene (SRY), located on the Y chromosome in genetic males, acts to induce the bipotential gonad to develop into a testis that will begin to produce androgens [3] . The hypothesis that sexual differentiation of the mammalian reproductive system is regulated by hormones from the differentiated gonad was first postulated by Alfred Jost over 70 years ago [4] . The Jost paradigm was based on classic studies by Jost [4] [5] [6] in which he demonstrated that removal of the fetal testis from male rabbits led to the regression of the Wolffian duct and maintenance of the Müllerian duct system. Jost also determined that grafting a testis adjacent to the ovary in female rabbit fetuses or placement of testosterone crystals near the ovary led to the development and retention of the Wolffian duct [4] . These studies by Jost and others [2] established the wellaccepted paradigm in mammals that development of a testis with synthesis of fetal androgens and anti-Müllerian hormone would induce regression of the Müllerian duct but promote stabilization and growth of the Wolffian duct in males. Thus, the female reproductive system develops in the absence of these hormones and has been considered the default or passive developmental pathway.
A very recent, exciting publication from Humphrey Yao and colleagues [7] has shown that, contrary to the accepted dogma that regression of the Wolffian duct in female embryos is a default developmental pathway due to lack of androgens, the regression of these ducts in female embryos is actively promoted by the orphan nuclear receptor COUP-TFII (chicken ovalbumin upstream promoter transcription factor II), which suppresses specific growth factor-mediated cross-talk between the mesenchyme and epithelium of the Wolffian duct leading to its regression. In an elegant series of studies utilizing a tamoxifen-inducible Wilms tumor-CreER model, Yao and colleagues demonstrated that conditional ablation of Coup-tfII in the Wolffian duct mesenchyme between days E12.5 and E16.5 led to retention of the Wolffian ducts in genetic XX female embryos. This retention of the Wolffian ducts in female Coup-tfII knockout embryos was not due to ectopic production or activation of the androgen pathway and was not blocked when pregnant dams carrying control and knockout embryos were exposed to the androgen antagonist flutamide. An organ culture system that allowed maintenance of E18.5 XX mesonephri with ovaries for up to 7 days showed that even after 7 days in culture, the Wolffian ducts were still present in the Coup-tfII knockout tissues along with the Müllerian ducts, confirming that the Wolffian ducts were stabilized and persisted after birth.
Yao and colleagues then investigated the mechanism by which loss of Coup-tfII in the female leads to retention of the Wolffian duct in the absence of androgens, focusing on growth factor signaling pathways known to promote Wolffian duct maintenance. Previous studies [8] [9] [10] had reported that the growth factors fibroblast growth factor 2 (Fgf2) and epidermal growth factor (EGF) both play a role in reproductive and urinary tract development. FGF receptor (FGFR) signaling has been shown to be critical for early metanephric mesenchymal patterning, nephron progenitor survival, nephrogenesis, and bladder mesenchymal patterning [8] . Okazawa et al. [9] demonstrated that FGFR expression is present in the Wolffian duct especially in the caudal region. Genetic ablation of the FGFR2 signaling pathway in the epithelium of the Wolffian duct resulted in loss of cell proliferation in the ductal epithelium, regression of the caudal portion of the Wolffian duct, and dilation of the cranial region. They also reported that strong expression of the FGFR2 ligand, FGF10, was present in both the metanephric mesenchyme and the mesenchyme of the coelom side, suggesting that this growth factor may be involved in maintenance of the Wolffian duct. EGF has also been shown to play a role [10] . Using an organ culture system of day E13 fetal genital tracts, Gupta et al. demonstrated that blocking EGF with an EGF antiserum led to loss of the Wolffian duct even in the presence of testosterone. Supplementation with exogenous EGF was able to rescue and maintain the duct system.
Yao and colleagues examined expression of EGF, FGFR, and FGF ligands in mesonephri of wild-type and Coup-tfII knockout mice. They observed no difference in EGF or FGFR expression but found that FGF7 and FGF10 expression were both markedly increased in the mesonephri of knockout XX fetuse at E14.5 and E16.5. Organ cultures of wild-type XX mesonephri in the presence of FGF7, FGF10, or FGF7 + FGF10 resulted in maintenance of the Wolffian ducts in these XX mesonephri. Furthermore, the effect of FGF signaling on Wolffian duct maintenance was transmitted through the extracellular signal-regulated kinase (pERK) pathway since treatment of Coup-tfII knockout mesonephri cultures with a p-ERK specific inhibitor led to elimination of the Wolffian ducts. This COUP-TFII regulatory pathway is also operative in genetic XY embryos since removal of the testis in Coup-TFII XY embryos led to maintenance of the Wolffian ducts despite the lack of androgens. Thus, in female embryos, COUP-TFII normally acts to inhibit expression of the FGFs that are necessary for Wolffian duct survival, leading to regression of these ducts (Figure 1 ), but in the absence of Coup-tfII, the Wolffian ducts in XX females remain. These novel findings by Yao and colleagues provide new insights into how reproductive tract development occurs in mammals and require modifying long accepted views on how reproductive tract development occurs in the female. It will also be important to consider defects in COUP-TFII expression in patients with reproductive tract anomalies.
